LIVE MARKET UPDATE

Showing posts with label sun pharma. Show all posts
Showing posts with label sun pharma. Show all posts

Friday, 8 July 2016

Equity Nifty News Updates - Today Stock Market Crash 2016

The Indian stock market opened the week on a sluggish note with investors not too keen on building up positions, despite positive global cues. Ahead of the onset of the reporting season, the mood in the market was by and large cautious. For more Live Stock Market Calls Visit Us www.marketmagnify.com/freetrial.php or Get Free Trials Just Call @911-110-48-06
 
Sensex ends 35 points downThe BSE benchmark Sensex ended up 34.62 points or 0.13% at 27,201.49, after having rallied to a high of 27,288.22 intraday. The Nifty50 of the National Stock Exchange, which rose to 8361.95, closed at 8337.90, recording a gain of 1.95 points or 0.02%.

Nifty breaks 8300, Sensex falls 100 pts; Tata Motors gains 2% :-
Lupin and Tata Motors were top gainers in early trade, up 2 percent each followed by Sun Pharma, BHEL, Hero MotoCorp and Aurobindo Pharma while Tata Steel, ITC, ONGC, Bharti Airtel, ICICI Bank, Idea Cellular and Bharti Infratel were losers.
Healthcare and FMCG stocks moved up. A few stocks from banking, consumer durables, power and realty sectors closed higher. Information technology stocks traded weak, while automobile, capital goods, metal and oil stocks turned in a mixed performance. Midcap and smallcap stocks were mostly subdued.

Lupin ended stronger by 7.8%. Dr Reddy's Laboratories moved up 2.7%, Cipla gained 2% and Sun Pharmaceutical Industries closed 0.7% up. Cadila Healthcare, Piramal Enterprises and GlaxoSmithKline Pharmaceuticals also closed on a firm note.

Wednesday, 11 May 2016

Top Stock Picks of the Pharma Sector-Equity Trading Tips



फार्मा की बड़ी कंपनियों में अच्छे रिटर्न मिल सकते हैं।

खासकर लार्जकैप में सन फार्मा, ल्यूपिन, डॉ. रेड्डीज, अरबिंदो फार्मा

मिडकैप में डिशमैन फार्मा और स्ट्राइड्स आर्कोलेब इन्वेस्टमेंट के लिए बेहतर विकल्प है।

फार्मा में क्यों हैं इन्वेस्टमेंट का मौका
माना जा रहा है कि अगले हफ्ते कई बड़ी फार्मा कंपनियों के रिजल्ट्स आएंगे, क्योंकि रुपए की कमजोरी और बड़ी दवाओं की लॉन्चिंग का फायदा कंपनियों की आय और मुनाफे पर दिखेगा।
लिहाजा शॉर्ट और लॉन्ग टर्म के लिए इन्वेस्टर्स इन स्टॉक्स पर दांव लगा सकते हैं।

शेयर बाजार समाचार और शेयर के चढ़ाव उतार तथा इन्वेस्टमेंट के लिए विसिट करे http://goo.gl/tT0pbo
  • Buy Sunpharma, Target Rs.1060
  • Buy Aurobindo Pharma and Dr Reddy

Thursday, 5 May 2016

Stock Cash Premium Tips: Sunpharma Up 3% and Nifty Open Higher

Stock market has opened with some gains on Thursday. Sensex is up 83.47 focuses at 25185.20 and Nifty up 22.90 focuses at 7729.45. Sun Pharma, Adani Ports, Hero MotoCorp, Tata Motors and Lupin are gainers while ITC, Tata Steel and Dr Reddy's Labs are washouts in the Sensex. The Indian rupee opened imperceptibly bring down by 4 paise at 66.59 for each dollar.
Join Stock Cash Power Service with 95% Accuracy www.marketmagnify.com/stock-cash-power.php

SKS Microfinance reported more than two-fold bounce in standalone net benefit at Rs 84.47 crore for the last quarter finished March 2016. 

Jindal Steel and Power (JSPL) contracted its merged net loss to Rs 371 crore in January-March quarter of 2015-16, improved by higher steel deals and cost improvement measures.

Wednesday, 30 March 2016

Equity Trading Tips with Sun Pharma Stock Price

Equity Quarterly Subscription visit 

Drug major Sun Pharma has forayed into the Japanese prescription market by acquiring 14 brands from Swiss drug firm Novartis for USD 293 million (over Rs 1,940 crore). 



According to the agreements signed by the parties, a wholly-owned subsidiary of Sun Pharma will acquire the portfolio consisting of 14 established prescription brands from Novartis for a cash consideration of USD 293 million, Sun Pharma said in a statement. 

Sun Pharma Stock Price: On March 29, 2016, Sun Pharmaceutical Industries closed at Rs 794.05, up Rs 0.00, or 0.00 percent. The 52-week high of the share was Rs 1200.70 and the 52-week low was Rs 706.40. 

The latest book value of the company is Rs 94.62 per share. At current value, the price-to-book value of the company was 8.39.